PFM
ARQT icon

Privium Fund Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Privium Fund Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
399,367
+78,395
+24% +$1.83M 1.92% 17
2026
Q1 		$7.56M Buy
320,972
+15,000
+5% +$383K 1.57% 21
2025
Q4 		$8.89M Hold
305,972
– – 1.64% 19
2025
Q3 		$5.77M Sell
305,972
-38,500
-11% -$607K 1.04% 19
2025
Q2 		$4.74M Buy
344,472
+18,763
+6% +$263K 1.02% 16
2025
Q1 		$5.09M Hold
325,709
– – 1.33% 17
2024
Q4 		$4.54M Buy
+325,709
New +$3.57M 1.03% 21

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Privium Fund Management's ARQT Position: Q2 2026 in Review

Privium Fund Management increased its Arcutis Biotherapeutics (ARQT) stake by 24% in Q2 2026, buying an estimated $1.83M and bringing the position to 399,367 shares worth $10.5M. The position accounts for 1.92% of the portfolio, ranked #17.

Privium Fund Management first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Privium Fund Management held 399,367 shares of Arcutis Biotherapeutics worth $10.5M as of Q2 2026.
  • Privium Fund Management bought 78,395 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.83M.
  • Arcutis Biotherapeutics made up 1.92% of Privium Fund Management's portfolio in Q2 2026, its #17 holding.
  • Privium Fund Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.